Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

76P - Leiomyosarcoma: Reviewing first-line options

Date

15 Mar 2024

Session

Poster Display session

Presenters

Laura Fernandez

Citation

Annals of Oncology (2024) 9 (suppl_2): 1-32. 10.1016/esmoop/esmoop102441

Authors

L. Fernandez1, I.C. Carrasco Garcia2, S. Diaz3, G. Martínez Bernal4, P. Sancho Marquez4, A.L. Moreno Vega4, M.J. Flor4

Author affiliations

  • 1 Medical Oncology, Hospital Universitario Juan Ramón Jimenez, 21005 - Huelva/ES
  • 2 Dept. Oncologia Medica, Hospital Universitario Virgen del Rocio, 41013 - Seville/ES
  • 3 Dept. Oncologia Medica, Hospital Universitario Virgen de Valme, 41014 - Seville/ES
  • 4 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 - Seville/ES

Resources

This content is available to ESMO members and event participants.

Abstract 76P

Background

Leiomyosarcomas are one of the most common types of sarcomas, with an estimated incidence between 10 and 20% of all sarcomas. Unfortunately, despite optimal locoregional treatments, leiomyosarcoma may relapse. At the European level through EORTC, efforts were made to assess different regimens in combination with doxorubicin for the treatment of metastatic unresectable leiomyosarcoma.

Methods

A total of 71 patients treated between 2010-2023 were retrospectively selected, all of whom had provided consent for the use of their data. To obtain a more homogeneous sample, only those patients treated in the first line with anthracyclines in monotherapy or in combination, and gemcitabine and docetaxel were selected from the initially identified group.

Results

A total of 71 patients were retrospectively reviewed, comprising 62 women and 9 men. Age at diagnosis was 53 years (range: 26-86 years). The most common location uterine in 46%. 52,11% (37 patients) exhibited metastatic onset. 64% had pulmonary involvement, predominantly followed by peritoneal localization. Survival in patients with non-metastatic onset, was 58 months (range: 51-64 months), compared to 24 months for metastatic onset (range: 13-34 months), p-value of 0.003. PFSl in different treatment lines: Doxorubicin (D): 8 months, Doxorubicin + dacarbazine(D+DTIC): 12 months, Doxorubicin+trabectedin(D+tra): 9 months, Epirubicin + ifosfamide (Epi+Ifo): 7 month, gemcitabine + docetaxel (Gem+Doc): 7 months and Doxorubicin + olaratumab (D+olara): 7 months, p=0,07. Overall survival (OS) D: 47 months, D+DTIC: 74 months, D+tra 42 month, Epi+Ifo: 30 months, Gem+Doc: 37 months and D+olara: 34 months.

Conclusions

Limitation of retrospective assessment. Slight increase in progression-free survival comparing with the literature. Epi+Ifo should not be a standard option in leiomyosarcoma, as literature data show a low response and limited disease control. However, in our historical series, it was a chosen line in 7 patients. OS, the combination of D+DTIC stands out, doubling overall survival compared to historical data. 86% reach second lines. Assessing PFS2 in treatment, a notable survival of 9 months with tra stands out, surpassing the average and comparing with the trabectedin second-line study showing a PFS of 4.2 months.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.